vimarsana.com

Page 5 - Global Program Head News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Matinas BioPharma : Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors

Matinas BioPharma : Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low

Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

$100 Off on SAT/ACT Prep Course - Enroll Now

$100 Off on SAT/ACT Prep Course – Enroll Now Published by GulteDesk April 24, 2021 $100 Off on SAT/ACT Prep course and Get Upto 40% Discount on Booking a tutor. Turito – A revolutionary Ed-tech platform initiated by YuppTV offers online tutoring for competitive exams such as SAT/ACT along with live interactive one-on-one tutoring for students of grade 3rd-12th. One-on-one Live Tutoring – Enroll Now & Get 40% Instant Discount Turito believes in helping students build a strong foundation in the early phases of their academic journey. Assessing their strengths and weaknesses at all stages starting from 3rd grade, the tutors ensure a significant improvement in the student’s grades with better conceptual understanding.

Axcella Announces Alison D Schecter, M D , as President of R&D

Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakravarthy, M.D., Ph.D., has decided to step down as the company’s Chief Medical Officer to pursue another opportunity.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.